Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology and research in psychedelics, announced today it has been included in the new AdvisorShares Psychedelics ETF, trading on the NYSE Arca under the ticker symbol "PSIL" (the "ETF").

PSIL offers exposure to biotechnology, pharmaceutical and life sciences companies that are leading the emerging psychedelics medicine industry. The ETF is actively managed and concentrates its investments in companies receiving the majority of their net revenue or allocating the majority of their assets from psychedelic drugs.

Kelsey Ramsden, MINDCURE President and CEO, said: "MINDCURE's inclusion in the AdvisorShares Psychedelics ETF is further validation of our strategy of integrating digital therapeutics with psychedelic medicine to improve mental health and increase productivity. MINDCURE is proud to be acknowledged as a leader in this emerging space and our inclusion in the ETF will increase investor awareness to the Company and the benefits of psychedelic treatment methods to improve mental health."

You can find additional information on the AdvisorShares Psychedelics ETF here.

About Mind Cure Health Inc.

MINDCURE is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The Company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based psychedelic-assisted therapies globally.  Learn more at mindcure.com, and follow us on LinkedIn, Facebook,Twitter, andInstagram.

On Behalf of the Board of Directors
Kelsey Ramsden, President & CEO
Phone: 1-888-593-8995

Forward-Looking Information

Forward-looking information is based on a number of key expectations and assumptions made by management of MINDCURE, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and MINDCURE's business, and the extent and duration of such impact; no change to laws or regulations that negatively affect MINDCURE's business; there will be a demand for MINDCURE's products in the future; no unanticipated expenses or costs arise; MINDCURE will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that iSTRYM will be developed, optimized and operate as contemplated within the psychedelics industry; that the Company will be effective in obtaining the patents applied for synthesizing ibogaine, or synthesizing ibogaine, or developing synthesized ibogaine for research, medical or commercial use; that MINDCURE will advance wellness worldwide; that iSTRYM will be brought to commercial deployment in the near term or otherwise or that it will reduce symptoms, improve quality of life, or support transformation and healing, or that the deployment may not occur at the scale or within the time frame contemplated.

Although MINDCURE has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those described in forward-looking information presented, there may be other factors that cause results, performance or achievements to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements as no forward-looking information can be guaranteed.

Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and MINDCURE does not undertake any obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.